Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 by William New, Intellectual Property Watch 1 Comment After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.]
WIPO Delegates Told Patent Information Essential, Given Revealing Data On Medicines Access and Trade 14/12/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment World Intellectual Property Organization patent law committee delegates heard a number of presentations this week on the relationship between patents and health, and access to medicines. The importance of patent information and accurate, up-to-date databases was underlined, particularly for procurement. The weight of intellectual property rights on the issue of access to medicines and prices and generic market entry was pointed out, but so were other factors, such as the small percentage of new drugs with added benefit, tariffs, and trade delays.
G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is “unparalleled,” and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found.
WHO, World Bank Say Half The World Population Cannot Access Essential Health Services 13/12/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment According to a report released today by the World Health Organization and the World Bank, at least half the world’s population is lacking access to essential health services. Out of pocket expenses related to health care are pushing millions of people into extreme poverty each year, the report says. Both organisations say they are committed to working with countries to increase access to essential health services.
Patents And Health Under Discussion At WIPO This Week: What Role For The UN IP Agency? 12/12/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment Patents are often involved in public health policy discussions, and are considered by some as playing a major role in the escalating prices of new medicines, creating access issues. The World Intellectual Property Organization committee on patent law this week is discussing the issue and is holding information sessions by the Medicines Patent Pool, World Health Organization, and the World Trade Organization.
Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 by Intellectual Property Watch Leave a Comment The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications.
WTO Ministerial: Challenging Start Despite Latin American Declaration For Multilateral Trade System 11/12/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment According to delegates speaking at the first plenary of the 11th Ministerial Meeting of the World Trade Organization in Buenos Aires today, member states face the risk of leaving with no joint agreement at all. For the much-debated e-commerce file for example there are eight different and irreconcilable proposals, the South African Ambassador Xavier Charm, chairman of the General Council, reported during the Welcome Session Sunday evening.
Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 by Tatum Anderson for Intellectual Property Watch 1 Comment The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon.
EPO Study Shows Rise In Patents On Next Generation Technologies 11/12/2017 by Intellectual Property Watch Leave a Comment The European Patent Office (EPO) today announced a study that showed “European patent applications related to smart connected objects are rising rapidly, achieving a growth rate of 54% in the last three years.”
WIPO Committee On Development and IP Agrees On Future Work, Keeps Several Issues Open 11/12/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization Committee on Development and Intellectual Property in its latest meeting agreed on a list of items to be discussed at its next session. No consensus was found on a potential biennial conference on IP and development, but discussions are set to continue. The committee also agreed to a suggestion to invite the team conducting an independent review on the implementation of the Development Agenda Recommendations to further explain some of their own recommendations.